Results 141 to 150 of about 70,538 (300)

An Implantable Scaffold Sequentially Releasing STING Agonist and B7‐H3 Antibody for Bone Metastasis Immunotherapy

Advanced Science, EarlyView.
We developed an implantable dual‐drug depot using GelMA for bone metastasis treatment, co‐delivering MSA‐2 and αB7‐H3‐loaded CaCO3 microparticles. Sustained release from GelMA scaffold enables MSA‐2 to activate STING signaling and enhance T‐cell infiltration and activation, while sequentially released αB7‐H3 blocks MSA‐2‐induced B7‐H3 upregulation ...
Qijun Lin, Hong Xiao, Shuai Fan, Kaimin Cai, Yanteng Xu, Xinwen Wang, Guanhong Chen, Chuandong Lang, Xinsheng Peng, Mingqiang Li, Yuhu Dai   +10 more
wiley   +1 more source

Practise of Immunoglobulin Replacement Therapy in Primary and Secondary Immunodeficiencies: A Single Centre Experience from Malaysia. [PDF]

Malays J Med Sci, 2023
Zahari NH, Abd Hamid IJ, Tuan Din SA, Hashim IF, Zainudeen ZT, Mohd Shariff N, Ahmad NH, Tay CY.   +7 more
europepmc   +1 more source

Thriving Without Transplant: A Case of X-Linked Hyper-IgM Syndrome with Near-Normal Quality of Life on IVIG

Journal of Human Immunity
IntroductionHyper-IgM syndrome (HIGM) is a rare primary immunodeficiency characterized by impaired immunoglobulin class-switch recombination, most commonly due to mutations in the CD40 ligand (CD40L) gene.
Nikhil Chowdary Peddi, Jenny Shliozberg
doaj   +1 more source

Glutamine Deprivation Triggers Tribbles Homolog 3 Dependent G‐Quadruplex Resolution to Maintain DNA Repair and Tumor Survival

Advanced Science, EarlyView.
Glutamine deprivation triggers transient DNA damage yet activates adaptive repair in hepatocellular carcinoma cells. We identify TRIB3 as a stress‐induced nuclear scaffold that associates with DDX5 and G‐quadruplex DNA atBRCA1 andRAD51AP1 promoters. TRIB3 loss increases G4 accumulation, suppresses HR gene transcription, elevates γ‐H2A.X, and sensitizes
Qiang Ji, Xuedan Sun, Zhangran Sun, Mengfan Li, Xinyu Cheng, Shuai Tian, Rick F. Thorne, Jinming Li, Guangzhi Liu, Mian Wu, Xiaoying Liu   +10 more
wiley   +1 more source

Immunoglobulin Replacement Therapy During COVID-19 Pandemic: Practical and Psychological Impact in Patients with Antibody Deficiency. [PDF]

J Clin Immunol, 2023
Maimaris J, O'Sullivan A, Underhill I, Green G, Symes A, Lowe D, Burns S, Campbell M, Elfeky R.   +8 more
europepmc   +1 more source

The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID)

The Turkish Journal of Pediatrics, 2005
Immunoglobulin replacement therapy is the essential treatment of B-cell deficiencies. Because of the high expense of therapy, optimal dose, infusion intervals and serum IgG levels should be well defined. Data of 19 X-linked agammaglobulinemia (XLA)
Benan Bayrakci, Fügen Ersoy, Ozden Sanal, Sebnem Kiliç, Ayşe Metin, Ilhan Tezcan   +5 more
doaj  

The New Formulations of Immunoglobulin Replacement Therapies and Future Aspects

Turkish Journal of Immunology
Immunoglobulin replacement therapy (IgRT) stands as the established method of treatment for numerous inborn errors of immunity (IEI). Over the past six decades, there have been notable advancements in the dosing, processing, and administration routes of ...
Elif Karakoç-aydıner
doaj   +1 more source

Ammonia Detoxification Inhibits Liver Metastasis by Reshaping Hepatic Microenvironment

Advanced Science, EarlyView.
Liver metastasis diverts aspartate into hyperactive pyrimidine synthesis, disrupting urea cycling and causing pathogenic ammonia accumulation. Ammonia dually reprograms the microenvironment by: (1) activating hepatic stellate cells (HSCs) into pro‐fibrotic metastasis‐associated fibroblasts (MAFs), and (2) suppressing anti‐tumor monocytes/macrophages ...
Sumin Sun, Haili Hu, Long Chen, Yuan Gao, Peng Sun, Liming Chen   +5 more
wiley   +1 more source

Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia? [PDF]

Front Immunol, 2023
Noto A, Cassin R, Mattiello V, Bortolotti M, Reda G, Barcellini W.   +5 more
europepmc   +1 more source

Hepatocyte BDNF Acts as a Novel Immune Checkpoint to Restrain TLR4‐Mediated Acute Hepatitis

Advanced Science, EarlyView.
This study identifies hepatocyte‐derived BDNF as an endogenous TLR4 antagonist that alleviates acute hepatitis. BDNF is downregulated in hepatocytes via REST‐mediated transcriptional repression during ALI/ALF. Mechanistically, BDNF binds to TLR4 on macrophages to suppress inflammation.
Weiwei Zhu, Yaqian Cui, Yongqiang Zhou, Yihui Zheng, Lijiang Huang, Leiming Jin, Qianhui Zhang, Pan Chen, Mengsha Lin, Jiaxi Ye, Yongqiang Xiong, Joo Young Huh, Xiang Hu, Xiaokun Li, Wu Luo, Guang Liang   +15 more
wiley   +1 more source